AstraZeneca

The Brain Tumor Therapeutics Market is projected to grow from USD 3.28 billion in 2024 to USD 5.28 billion by 2030, driven by advances in healthcare technologies and increased investment in oncology research. Key areas explored include market penetration, development, diversification, competitive assessment, and product innovation. Challenges include high R&D costs and regulatory hurdles. Opportunities lie in personalized medicine and novel drug delivery systems.

A Phase II trial of AstraZeneca’s Fasenra (benralizumab) for eosinophilic asthma and COPD showed a significant improvement over standard care, with 45% of patients experiencing exacerbations compared to 74% in the steroid group. Fasenra was well-tolerated, with no fatal adverse events reported.

Benralizumab, a monoclonal antibody, outperformed steroids in reducing asthma and COPD symptoms, with fewer attacks and improved quality of life, according to a clinical trial published in The Lancet Respiratory Medicine.

QIAGEN plans to relocate QIAstat-Dx operations to a new 8,000-square-meter site in Barcelona by early 2026, supporting syndromic testing for infectious diseases and precision medicine, with R&D, manufacturing, sales, marketing, and regulatory operations, featuring digitalized production lines and LEED Platinum certification, aiming to strengthen diagnostic capabilities and support partnerships with Eli Lilly and AstraZeneca. The system currently has FDA clearance for four panels and CE-marking for two panels under IVDR.

Ascentage Pharma's olverembatinib, a third-generation BCR-ABL inhibitor, has its new indication for adult patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant and/or intolerant of first-and second-generation tyrosine kinase inhibitors (TKIs) included in the China 2024 National Reimbursement Drug List (NRDL), effective January 1, 2025.

The U.S. clinical trials market is projected to reach $57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominated in 2024, with oncology holding the largest revenue share. Key players include IQVIA, Fortrea Inc., PAREXEL, and Thermo Fisher Scientific.

A trial found that a single high-dose injection of benralizumab, targeting eosinophils to reduce lung inflammation, was more effective than steroid tablets in treating severe asthma and COPD attacks, cutting the need for further treatment by 30%.

The U.S. clinical trials market is projected to reach $57.79 billion by 2030, driven by chronic disease prevalence and increased demand. Phase III trials dominated in 2024, with oncology leading by indication. Key players include IQVIA, Fortrea Inc., and PAREXEL International Corporation.

AstraZeneca's Phase III CAPItello-281 trial showed Truqap (capivasertib) + abiraterone + ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer. Early OS signs also suggest benefit, with ongoing trial for further assessment. Truqap + Faslodex was approved in the EU for ER-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations.